Medigene AG

Medigene AG is an immuno-oncology platform company focused on developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Their End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique attributes, which are utilized in various therapeutic modalities such as TCR-T therapies, TCR-guided T cell engager therapies and TCR-natural killer cell therapies for both their in-house product pipeline and partnering. Medigene’s lead TCR-T program, MDG1015, targets the cancer-testis antigen NY-ESO-1/LAGE-1a and has received IND approval from the FDA.

Medigene has a strong focus on innovation, evident in their proprietary technologies that aim to enhance the effectiveness of TCR therapies. These technologies include the PD1-41BB and CD40L-CD28 costimulatory switch proteins, which help to overcome the immunosuppressive tumor microenvironment. Medigene collaborates with various partners, including BioNTech, Regeneron and WuXi Biologics, to further develop and commercialize their TCR-guided therapies.

Medigene AG does not explicitly state any information about the job flexibility or work-from-home options offered to their employees on their website or job postings.

Medigene AG offers employees a competitive compensation package and is committed to supporting their professional development. The company values collaboration, empowers individuals and teams, fosters innovation, prioritizes fast decision-making, and focuses on solutions. This culture and the company's expertise in T cell biology and immunology provide a stimulating work environment for employees.

Medigene AG is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Their End-to-End Platform generates optimal 3S (sensitive, specific, and safe) T cell receptors that are utilized in multiple therapeutic modalities, such as TCR-T therapies, TCR-guided T cell engager therapies, and TCR-natural killer cell therapies for both its in-house product pipeline and partnering. The company focuses on developing highly innovative, complementary treatment options for various cancer types by harnessing the body's own defense mechanisms.

Medigene fosters a collaborative and empowering work environment that values innovation and fast decision-making. They are passionate about their mission to develop differentiated T cell receptor engineered T cell (TCR-T) therapies to address the needs of patients with solid tumors. Their culture is supportive of delivering on this vision, emphasizing teamwork, individual and team empowerment, and a solution-oriented approach.

Medigene AG values a diverse, equitable, and inclusive workplace. They believe a culture that embraces diverse perspectives and backgrounds is essential for innovation and success. Medigene fosters a welcoming environment where everyone feels valued and respected, empowering individuals and teams to reach their full potential. They are committed to creating an inclusive workplace that reflects the communities they serve, recognizing the importance of diversity in the pursuit of scientific advancement and patient care.